We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Dynavax Technologies Corporation
94 own
156 watching
Current Price
$11.69
$-0.19
(-1.6%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,491.42M
52-Week High
17.48
52-Week Low
7.26
Average Volume
1.48M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,491.42M52-Week High17.4852-Week Low7.26Average Volume1.48MDividend Yield--P/E Ratio--What does the Dynavax Technologies Corporation do?
Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The company's lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Read More
How much money does Dynavax Technologies Corporation make?
News & Events about Dynavax Technologies Corporation.
Globe Newswire
1month ago
Saint-Herblain (France), December 30, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001. In study VLA2001-3071, a subset of ...
Zolmax
1month ago
Dynavax Technologies Co. (NASDAQ:DVAX Get Rating) Director Andrew A. F. Hack sold 1,500,000 shares of the stock in a transaction dated Tuesday, December 6th. The shares were sold at an average price of $11.60, for a total transaction of $17,400,000.00. Following the completion of the transaction, ...
Zolmax
3 months ago
Yousif Capital Management LLC acquired a new stake in Dynavax Technologies Co. (NASDAQ:DVAX Get Rating) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 108,179 shares of the biopharmaceutical companys stock, valued at ...
Globe Newswire
3 months ago
-- Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clovers lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4 2022-- -- New data demonstrating superiority as a heterologous booster compared to inactivated ...
Globe Newswire
4 months ago
Saint-Herblain (France), September 26, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities. The Company had previously communicated that it would invest in further development of a potential second-...
Frequently Asked Questions
Frequently Asked Questions
What is Dynavax Technologies Corporation share price today?
Can Indians buy Dynavax Technologies Corporation shares?
How can I buy Dynavax Technologies Corporation shares from India?
Can Fractional shares of Dynavax Technologies Corporation be purchased?
What are the documents required to start investing in Dynavax Technologies Corporation stocks?
What is today’s traded volume of Dynavax Technologies Corporation?
What is today’s market capitalisation of Dynavax Technologies Corporation?
What is the 52-Week High and Low Range of Dynavax Technologies Corporation?
What percentage is Dynavax Technologies Corporation down from its 52-Week High?
What percentage is Dynavax Technologies Corporation up from its 52-Week Low?
Current Price
$11.69
$-0.19
(-1.6%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.